Clinical Trial Update: Allogenic NK Cell Transfusion Azacitidine MDS-EB [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update investigating allogeneic NK cell transfusion with azacitidine in MDS-EB, spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome with Excess Blasts
• Myelodysplastic Syndrome with Excess Blasts-1 2

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Allogeneic NK cell transfusion (natural killer cell therapy)

Snippet

Sponsor: The Second Hospital of Shandong University | Conditions: MDS-EB | Phase 1, Phase 2 | Status: UNKNOWN